Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Johnson and Johnson
Daiichi Sankyo
McKinsey
QuintilesIMS
Fuji
Deloitte
Express Scripts
Accenture

Generated: November 20, 2018

DrugPatentWatch Database Preview

Indium in-111 pentetreotide kit - Generic Drug Details

« Back to Dashboard

What are the generic sources for indium in-111 pentetreotide kit and what is the scope of indium in-111 pentetreotide kit freedom to operate?

Indium in-111 pentetreotide kit is the generic ingredient in one branded drug marketed by Mallinkrodt Nuclear and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are twenty-three drug master file entries for indium in-111 pentetreotide kit. One supplier is listed for this compound.

Summary for indium in-111 pentetreotide kit
Synonyms for indium in-111 pentetreotide kit
111In-Pentetreotide
139096-04-1
159201-00-0
2-[2-[[2-[[1-[[10-(4-aminobutyl)-16-benzyl-4-(1,3-dihydroxybutan-2-ylcarbamoyl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl
AC1MIXSA
AM015611
D02108
Indate(1-), (N-(2-((2-(bis(carboxymethyl)amino)ethyl)(carboxymethyl)amino)ethyl)-N-(carboxymethyl)glycyl-D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-L-cystei
Indium In 111 pentetreotide (USP)
Indium in 111 pentetreotide [USAN]
INDIUM(3+) ION HYDROGEN 2-{[2-({[(1-{[10-(4-AMINOBUTYL)-16-BENZYL-4-[(1,3-DIHYDROXYBUTAN-2-YL)CARBAMOYL]-7-(1-HYDROXYETHYL)-13-(1H-INDOL-3-YLMETHYL)-6,9,12,15,18-PENTAOXO-1,2-DITHIA-5,8,11,14,17-PENTAAZACYCLOICOSAN-19-YL]CARB
LS-186657
MP-1727
OctreoScan
OctreoScan (TN)

US Patents and Regulatory Information for indium in-111 pentetreotide kit

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mallinkrodt Nuclear OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for indium in-111 pentetreotide kit

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mallinkrodt Nuclear OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994 ➤ Sign Up ➤ Sign Up
Mallinkrodt Nuclear OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994 ➤ Sign Up ➤ Sign Up
Mallinkrodt Nuclear OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994 ➤ Sign Up ➤ Sign Up
Mallinkrodt Nuclear OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Johnson and Johnson
Daiichi Sankyo
McKinsey
QuintilesIMS
Fuji
Deloitte
Express Scripts
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.